The estimated Net Worth of Foundation Harsaul is at least $25 Миллион dollars as of 13 January 2020. Foundation Harsaul owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over $24,958,680 and over the last 5 years Foundation sold OSMT stock worth over $0.
Foundation has made over 1 trades of the Osmotica Pharmaceuticals Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently Foundation bought 1,250,000 units of OSMT stock worth $6,250,000 on 13 January 2020.
The largest trade Foundation's ever made was buying 1,250,000 units of Osmotica Pharmaceuticals Plc stock on 13 January 2020 worth over $6,250,000. On average, Foundation trades about 1,250,000 units every 0 days since 2020. As of 13 January 2020 Foundation still owns at least 22,485,297 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Foundation Harsaul stock trades at the bottom of the page.
Foundation's mailing address filed with the SEC is EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA, R1, 0.
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman и Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include: